Instrument Inactif

Communiqués PFIZER Euronext Paris

Actions

PFZ

US7170811035

Produits pharmaceutiques

Cours en clôture Euronext Paris Autres places de cotation
-	-

13:35	Pfizer annonce des résultats de phase 3 positifs pour LITFULO chez les patients atteints de vitiligo non segmentaire	CI
13:04	Bristol Myers relève ses prévisions pour 2026, porté par l'Eliquis et ses nouveaux traitements	RE

Communiqués

12:46	Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo	BU
29/07	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union	BU
22/07	FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer	BU
16/07	AM Best Affirms Credit Ratings of Blue Whale Re Ltd	AQ
13/07	“2” Does Not Provide Written Description Support For “1”: Federal Circuit Affirms District Court’s Invalidation Of Patent	AQ
10/07	Pfizer : U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPrescription MedicinesMedicines	PU
10/07	U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	BU
06/07	“A One-Carbon Poison Pill”: Enanta v. Pfizer And The “Typo” That Lost A Priority Date	AQ
24/06	Pfizer Declares Third-Quarter 2026 Dividend	BU
24/06	Pfizer : FDA Approves Pfizer’s IBRANCE Regimen for HR , HER2 Metastatic Breast Cancer Frontline Maintenance	PU
24/06	FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance	BU
23/06	Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts	BU
22/06	Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer	BU
18/06	Pfizer Announces Chief Financial Officer Transition	BU
08/06	U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	BU
06/06	Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide	BU
01/06	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
31/05	Pfizer : BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	PU
31/05	Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	BU
30/05	TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer	BU
29/05	Pfizer : European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech COVID 19 Vaccine	PU
29/05	Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer	BU
29/05	Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines	BU
27/05	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
20/05	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results	BU